Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study
This real-world analysis indicates that 3-month goserelin 10.8 mg is non-inferior to monthly 3.6 mg among premenopausal women with breast cancer in terms of 12-month rwEFS rate. These findings may support the use of the 3-month goserelin 10.8 mg as an alternative treatment option to monthly goserelin 3.6 mg for this patient population.
Authors
- Jon G. Tepsick (ORCID: https://orcid.org/0000-0001-6035-7800)
- Lonnie Brent
- Y. Wang
- Virginia Kaklamani (ORCID: https://orcid.org/0000-0002-3313-8458)
- Kelly McCann (ORCID: https://orcid.org/0000-0001-8233-6242)
- Noran Osman
- Nancy Martin
- Joan Cannon
- Vincent A. Miller (ORCID: https://orcid.org/0000-0003-1667-3771)
- Prithviraj Vikramsinh Mandora
Institutions
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Deerfield (United States) (US)
- Concert Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1007/s10549-025-07656-z
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00